Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects

NCT01780077 is registered in ClinicalTrials.gov with RXi Pharmaceuticals, Corp. as lead sponsor.

NCT NCT01780077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01780077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects
Lead sponsor
RXi Pharmaceuticals, Corp.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2012
Completion date
November 30, 2014
Enrollment
15 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cicatrix, scar prevention